Search | Clinical Trials Finder

Conditions: SARS (Disease)
Interventions: Cyclosporine, Standard of Care Treatment; Drug · Other
Lead sponsor: Bryan Burt, MD; Other
Eligibility: 18 Years to 90 Years
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Keratoconus
Interventions: Riboflavin 5'-phosphate in 20% dextran ophthalmic solution) 0.146% with UV light, Riboflavin 5'-phosphate in 20% dextran ophthalmic solution) 0.146% without UV light; Drug
Lead sponsor: Joseph B. Ciolino, MD; Other
Eligibility: 18 Years to 50 Years
Enrollment: 216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Non-verbal Learning Disorder, Autism Spectrum Disorder, Autism
Interventions: Open-label Treatment with Omega-3 Fatty Acids + Inositol, Open-label Treatment with N-acetylcysteine; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 5 Years to 17 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Chronic Myeloproliferative Disorders, Leukemia, Myelodysplastic/Myeloproliferative Diseases
Interventions: cyclophosphamide, cyclosporine, fludarabine phosphate, methylprednisolone, therapeutic allogeneic lymphocytes, thiotepa, allogeneic bone marrow transplantation, biological therapy, bone marrow ablation with stem cell support, bone marrow transplantation, chemotherapy, leukocyte therapy, non-specific immune-modulator therapy, peripheral blood lymphocyte therapy, peripheral blood stem cell transplantation, radiation therapy; Drug · Procedure
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 10 Years to 50 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2007
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Lung Cancer
Interventions: antitumor drug screening assay; Other
Lead sponsor: The Cleveland Clinic; Other
Eligibility: Not listed
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Melanoma (Skin)
Interventions: NY-ESO-1 157-165 (165V), Nivolumab, gp100:280-288 (288V), Montanide ISA 51 vegetable grade (VG), Ipilimumab, Apheresis Procedure; Biological · Drug · Procedure
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 16 Years and older
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2023
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: X-Linked Retinitis Pigmentosa
Interventions: AAV5-hRKp.RPGR, No intervention (Follow-Up assessment); Biological · Other
Lead sponsor: MeiraGTx Ocular UK Ltd; Industry
Eligibility: 5 Years and older · Male only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 2
States / cities: Boston, Massachusetts • Ann Arbor, Michigan

Conditions: Acute Coronary Syndrome
Interventions: Placebo, St. Johns Wort; Drug
Lead sponsor: Lancaster General Hospital; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Lancaster, Pennsylvania

Conditions: Infertility
Interventions: Office hysteroscopy; Device
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Raleigh, North Carolina

Conditions: Lung Cancer
Interventions: autologous tumor cell vaccine, therapeutic autologous dendritic cells, adjuvant therapy, biological therapy, conventional surgery, surgery, tumor cell derivative vaccine, vaccine therapy; Drug · Procedure
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Blood Pressure, Hypertension, Mhealth
Interventions: PACESETTER; Device
Lead sponsor: Northern California Institute of Research and Education; Other
Eligibility: 18 Years to 80 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 4
States / cities: San Francisco, California • Charleston, South Carolina • Columbia, South Carolina + 1 more

Conditions: Breast Cancer, Invasive Breast Cancer
Interventions: Pre-neoadjuvant radiotherapy (NART) biopsy, Neoadjuvant radiotherapy, Unilateral total mastectomy with axillary lymph node dissection; Diagnostic Test · Radiation · Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Colon Cancer, Peripheral Neuropathy
Interventions: Cryotherapy Gloves; Device
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Mineola, New York • New York, New York

Conditions: Oral Cavity Squamous Cell Carcinoma
Interventions: NisinZ® P, Surgery (non-interventional, standard of care); Drug · Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Wounds and Injuries
Interventions: Processed Amniotic Fluid, Standard of Care Wound Treatment Regimen; Drug · Other
Lead sponsor: University of Utah; Other
Eligibility: 18 Years to 85 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Labral Tear, Glenoid
Interventions: 1.5 Tesla magnet MR arthrography, 3 Tesla magnet non-contrast MRI; Radiation
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Royal Oak, Michigan

Conditions: Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions: Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Elastography, Multigated Acquisition Scan, Necitumumab, Osimertinib; Procedure · Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 15
States / cities: Duarte, California • Palo Alto, California • Sacramento, California + 7 more

Conditions: Accident, Traffic
Interventions: Tiny Cargo, Big Deal/Abróchame Bien, Cuídame Bien (TCBD/ABCB) Basic Intervention, Tiny Cargo, Big Deal/Abróchame Bien, Cuídame Bien (TCBD/ABCB) Enhanced Intervention; Behavioral
Lead sponsor: Ann & Robert H Lurie Children's Hospital of Chicago; Other
Eligibility: 6 Months to 10 Years
Enrollment: 513 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Inoperable Stage I/II Non-small Cell Lung Cancer
Interventions: Stereotactic Body Radiation Therapy (SBRT); Radiation
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2018
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Abdominal Aortic Aneurysm
Interventions: Endovascular AAA repair with InCraft®; Device
Lead sponsor: Cordis US Corp.; Industry
Eligibility: 20 Years and older
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Hyperhidrosis
Interventions: gravimetric; Other
Lead sponsor: Botanix Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Carpinteria, California

Conditions: Pediatric Obesity
Interventions: Topiramate, Phentermine; Drug
Lead sponsor: Janey Pratt; Other
Eligibility: 12 Years to 25 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Colorectal Cancer
Interventions: everolimus, antiangiogenesis therapy, biopsy, diagnostic procedure, gene expression analysis, immunohistochemistry staining method, laboratory biomarker analysis, mutation analysis, protein tyrosine kinase inhibitor therapy, reverse transcriptase-polymerase chain reaction; Drug · Procedure
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Brain Tumor, Pediatric Brain Tumor, Pediatric Cancer
Interventions: Diffusion tensor imaging (DTI), Resting state functional connectivity MRI (rs-fcMRI), Wechsler Intelligence Scale for Children - 5th edition (WISC-V), California Verbal Learning Test (CVLT-C), Beery Test of Visual Motor Integration 6th edition, Grooved Pegboard, PedsQL Multidimensional Fatigue Scale, MRI; Diagnostic Test · Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 6 Years to 16 Years
Enrollment: 42 participants
Timeline: 2017 – 2027
U.S. locations: 4
States / cities: New York, New York • Dallas, Texas • Seattle, Washington

Search by objective public record fields.

Cyclosporine For The Treatment Of COVID-19(+)

A Randomized Clinical Trial of Ex Vivo Corneal Cross-Linking of Donor Keratoplasty Tissue for Keratoconus Used for Keratoplasty in Keratoconus Patients

Natural Treatments for the Management of Emotional Dysregulation in Youth With Non-verbal Learning Disability (NVLD) and/or Autism Spectrum Disorders (ASD)

Peripheral Stem Cell Transplant in Treating Patients With High-Risk Leukemia

Cerebrospinal Fluid Levels of Erlotinib in Patients Receiving Erlotinib For Stage III Non-Small Cell Lung Cancer

Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma

A Follow-on Study for Second-Eye Treatment for Participants Previously Treated With Gene Therapy for X-Linked Retinitis Pigmentosa (XLRP)

Pharmacodynamic Study on Efficacy of Clopidogrel With St. John's Wort

SIS Versus Office Hysteroscopy for Uterine Cavity Evaluation Prior to IVF

Vaccine Therapy in Treating Patients Who Are Undergoing Surgery for Stage IB, Stage II, or Stage IIIA Non-Small Cell Lung Cancer

PACESETTER: Program to Avoid Cerebrovascular Events Through Systematic Electronic Tracking and Tailoring of an Eminent Risk-factor

A Study of an Alternative Treatment Approach (Preoperative Radiotherapy, Then Mastectomy, Then Immediate Reconstruction Surgery) in People With T4 Breast Cancer

Cryotherapy & Oxaliplatin

Nisin in Oral Cavity Squamous Cell Carcinoma (OCSCC)

Processed Amniotic Fluid (pAF) for the Treatment of Chronic Wounds

Applicability of 3T Shoulder MRI in Detection of Labral Pathology

Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor

Tiny Cargo, Big Deal! An ED-Based Study of Child Passenger Safety Behaviors

A Phase I/II Trial of Stereotactic Body Radiation Therapy

A Multicenter, Open Label, Prospective, Non-randomized Study of the InCraft® Stent Graft System in Subjects With Abdominal Aortic Aneurysms (INSPIRATION)

A Non-Interventional Study To Assess Sweating

Medications After Adolescent Bariatric Surgery

Everolimus in Treating Patients With Advanced or Metastatic Colorectal Cancer That Did Not Respond to Previous Therapy

Understanding the Late Effects of Surviving a Pediatric Brain Tumor